STAAR Surgical Reports Third Quarter Results
Published on November 7, 2025
LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a leading developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has reported results for the third quarter ended September 26, 2025. Net sales were $94.7 million for the third quarter of 2025, an increase compared with $88.6 million in the prior year quarter as well as compared with $44.3 million in the second quarter of 2025.